An Exciting New Covid Vaccine And An ETF Which May Benefit
I love it when my work intersects with real life.
This morning, I came across an article in the New York Times featuring a new Covid vaccine from Sanofi (SNY) and GlaxoSmithKline plc (GSK) that appears to hold great promise.
Photo by Towfiqu barbhuiya on Unsplash
Its Phase 3 clinical trials appear to reveal that the vaccine could be an extremely effective booster shot for individuals who have already received one of the mRNA vaccines in current use. Even more intriguing, since this vaccine is based on the conventional approach, it may not require the ultracold storage needed for mRNA vaccines. As a result, it could be a more likely candidate for use in countries such as Africa.
Courtesy of the gift article provision of my NYT subscription, here is a link to the article, for any interested in reading further.
As I read the article, I couldn't help but smile to myself at this development. You see, SNY and GSK are the 3rd- and 4th-heaviest weighted stocks in a relatively new ETF I just finished reviewing for Seeking Alpha.